Ultragenyx Pharmaceutical, Inc. (RARE)
15.22
+0.47
(+3.19%)
USD |
NASDAQ |
Oct 02, 16:00
15.33
+0.11
(+0.72%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Net Income (Quarterly) : -92.00M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -92.00M |
| March 31, 2026 | -185.00M |
| December 31, 2025 | -129.00M |
| September 30, 2025 | -180.41M |
| June 30, 2025 | -114.95M |
| March 31, 2025 | -151.08M |
| December 31, 2024 | -133.38M |
| September 30, 2024 | -133.52M |
| June 30, 2024 | -131.60M |
| March 31, 2024 | -170.68M |
| December 31, 2023 | -123.19M |
| September 30, 2023 | -159.65M |
| June 30, 2023 | -159.83M |
| March 31, 2023 | -163.97M |
| December 31, 2022 | -151.83M |
| September 30, 2022 | -245.11M |
| June 30, 2022 | -158.16M |
| March 31, 2022 | -152.32M |
| December 31, 2021 | -122.46M |
| September 30, 2021 | -73.00M |
| June 30, 2021 | -122.43M |
| March 31, 2021 | -136.14M |
| December 31, 2020 | -24.01M |
| September 30, 2020 | -68.84M |
| June 30, 2020 | 25.32M |
| Date | Value |
|---|---|
| March 31, 2020 | -119.02M |
| December 31, 2019 | -93.80M |
| September 30, 2019 | -112.99M |
| June 30, 2019 | -99.17M |
| March 31, 2019 | -96.76M |
| December 31, 2018 | -87.83M |
| September 30, 2018 | -87.31M |
| June 30, 2018 | -52.73M |
| March 31, 2018 | 30.25M |
| December 31, 2017 | -81.73M |
| September 30, 2017 | -79.23M |
| June 30, 2017 | -72.89M |
| March 31, 2017 | -68.29M |
| December 31, 2016 | -71.29M |
| September 30, 2016 | -64.91M |
| June 30, 2016 | -56.92M |
| March 31, 2016 | -52.76M |
| December 31, 2015 | -55.22M |
| September 30, 2015 | -39.23M |
| June 30, 2015 | -29.79M |
| March 31, 2015 | -21.38M |
| December 31, 2014 | -16.74M |
| September 30, 2014 | -15.85M |
| June 30, 2014 | -13.58M |
| March 31, 2014 | -13.63M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| AbbVie, Inc. | 3.604B |
| Biogen, Inc. | 97.50M |
| BioMarin Pharmaceutical, Inc. | 44.76M |
| Ionis Pharmaceuticals, Inc. | -114.65M |
| Regeneron Pharmaceuticals, Inc. | 1.297B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 214.00M |
| Total Expenses (Quarterly) | 306.00M |
| EPS Diluted (Quarterly) | -0.9028 |
| Enterprise Value | 2.404B |
| Gross Profit Margin (Quarterly) | 80.37% |
| Profit Margin (Quarterly) | -42.99% |
| Earnings Yield | -38.38% |
| Normalized Earnings Yield | -38.41 |